YOU WONT BELIEVE: 25 - You Need To See This

Do Wall Street Analysts Like Eli Lilly Stock?

Eli Lilly stock has outperformed the broader market over the past year, and Wall Street analysts remain optimistic about the stock’s prospect.

Barchart · May 31, 2024

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

StockNews.com · May 23, 2024

It's Time for Over-the-Counter Ozempic

There's an easy way to lower the cost of next-generation weight-loss drugs.

Reason · May 22, 2024

Stocks Sink on Concern the Fed Will Keep Interest Rates Higher for Longer

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -1.57%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.92%. US stock indexes Tuesday finished sharply lower. Signs of persistent wage pressure pushed bond...

Barchart · Apr 30, 2024

Stock Market Today: Stocks Sell Off Ahead of Fed Decision

Stocks sold off sharply Tuesday as anxiety set in ahead of Wednesday's policy statement from the Federal Reserve.

Kiplinger · Apr 30, 2024

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

Barchart · Apr 18, 2024

Zepbound Shows Promise In Treating Sleep Apnea

Eli Lilly's Zepbound drug shows promise in treating obstructive sleep apnea by reducing symptoms and promoting weight loss.

Top News · Apr 18, 2024

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

The Guardian - UK · Mar 28, 2024

Alzheimer’s ‘breakthrough’ stalls: why a much-hyped drug is facing approval delays

The benefits of drugs such as donanemab, aducanumab and lecanemab are proving harder to quantify than potential harms, experts say

The Guardian - AU · Mar 23, 2024

Stocks Give Up Early Gains and Close Lower as Chip Stocks Retreat

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.65%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.18% and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.53%. Stock indexes on Friday gave up early gains and closed moderately lower. Stocks on...

Barchart · Mar 8, 2024